Bonviva ibandronate regulatory update

ROCZ and GSK submitted an MAA for once-monthly oral Bonviva, a bisphosphonate that inhibits osteoclast-mediated bone resorption, to treat postmenopausal osteoporosis. The EC approved a once-daily form...